World Journal of Nuclear Medicine最新文献_第10页

FDG PET-CT in Clinical Management of a Rare Case of Primary Hepatic Lymphoma: Role and Challenges FDG PET-CT 在罕见原发性肝淋巴瘤临床治疗中的作用与挑战作用与挑战

IF 0.6 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

World Journal of Nuclear Medicine

Pub Date : 2023-12-04 DOI: 10.1055/s-0043-1774734

T. Jain, Naveen Gupta, Hemant Malhotra, Lalit Mohan Sharma

Abstract The common differential diagnoses for multiple space-occupying hepatic lesions (SOL) are metastases, multifocal hepatocellular carcinoma, and abscess. Primary hepatic lymphomas are rare entities that present many challenges with regard to their management. Fluorodeoxyglucose positron emission tomography-computed tomography is extensively used for the staging and response assessment of lymphomas but it can be challenging and difficult to interpret in cases with isolated liver involvement. We hereby present the case of an 82-year-old lady who presented with multiple liver SOL.

多发占位性肝病变(SOL)的常见鉴别诊断为转移、多灶性肝细胞癌和脓肿。原发性肝淋巴瘤是罕见的实体，提出了许多挑战，关于他们的管理。氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描广泛用于淋巴瘤的分期和反应评估，但在孤立肝脏受累的情况下，它可能具有挑战性和难以解释。我们在此报告一位82岁的女士，她表现出多发性肝脏SOL。

引用次数: 0

Familial MEN1 Syndrome Diagnosed on Functional Imaging: A Case Report with Clinical and Genetic Correlation 通过功能成像诊断的家族性 MEN1 综合征：与临床和遗传相关的病例报告

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-12-04 DOI: 10.1055/s-0043-1768448

Ashwini Kalshetty, Ashwini Chalikandy

Abstract Multiple endocrine neoplasia, type 1 (MEN1) syndrome is an autosomal dominant disease characterized by tumors involving parathyroid, pituitary, and pancreas. The diagnosis is mostly clinical and by the presence of MEN1 gene mutation. We present a case with initial presentation of neuroendocrine tumor of pancreas whose ancillary findings on 68 Ga-DOTATATE positron emission tomography-computed tomography helped in raising suspicion of MEN1, which was confirmed on genetic testing and family history. We emphasize the importance of using gestalt approach in such cases to avoid misdiagnosis or delay. Additionally, we describe the clinical profile of affected family members with their MEN1 gene mutation status, highlighting the gestalt approach again to uncover the unknowns.

多发性内分泌肿瘤1型综合征(MEN1)是一种常染色体显性遗传病，以累及甲状旁腺、垂体和胰腺的肿瘤为特征。诊断主要是临床和MEN1基因突变的存在。我们报告一个最初表现为胰腺神经内分泌肿瘤的病例，其68ga - dotatate正电子发射断层扫描-计算机断层扫描的辅助发现有助于提高MEN1的怀疑，并通过基因检测和家族史证实。我们强调在这种情况下使用格式塔方法的重要性，以避免误诊或延误。此外，我们描述了具有MEN1基因突变状态的受影响家庭成员的临床概况，再次强调格式塔方法以揭示未知因素。

引用次数: 0

Theranostics in Developing Countries: Addressing Challenges and Potentials from Training to Practice. 发展中国家的Theranostics：应对从培训到实践的挑战和潜力。

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-09-20 eCollection Date: 2023-09-01 DOI: 10.1055/s-0043-1774733

Akram Al-Ibraheem

In recent times, nuclear medicine (NM) has witnessed noteworthy expansion, presenting several technologies and procedures that aid in the identification and management of various illnesses and disorders. The current era of globalization has posed difficulties for health care systems in managing the escalating incidence of noncommunicable diseases (NCDs) in developing countries.1 The use of radionuclide pairs for both diagnosis and treatment, known as theranostics, has become increasingly popular in developing countries.2 This is due to the availability of more resources, expertise, and personnel. Although the idea of combining therapyand diagnosis has been studied and utilized formany years, recent advancements in cancer genomics and hallmarks have led to significant progress in the field of theranostics over the past two decades. Nowadays, NM theranostics are improving the prognosis of cancer patients through the use of lutetium-based radionuclide therapies, whichhavebeenvalidated in phase III clinical trialswith high confidence.3,4 To date, many Southeast Asian, Middle Eastern, and Latin American countries have continuously offered advanced NM services.5–7 Some of these countries serve as exemplary models in the developing world, as they leverage their limited resources to generate numerous radionuclides, conduct practical research projects, and significantly contribute to the progress of theranostics. Additionally, they have augmented the size of their NM workforce by offering specialized NM training programs as well as fellowship programs. Although theranostics has made substantial strides and improvements, a discernible discrepancy persists among developing countries. This disparity is particularly noticeable in theMiddle East, where numerous countries are embroiled inwars and conflicts.8 These developing countries are currently encountering difficulties keeping up with the latest advancements in theranostics. Presently, there are over 2,000 NM centers in the region.9 Several countries in the region have made investments in establishing production facilities. This investment has contributed to a noticeable increase in the local supply of essential radiopharmaceuticals. It is noteworthy that several centers of excellence in NM are currently involved in providing early experience with innovative theranostic agents, despite several limitations. This has been made possible due to flexible national and institutional regulations that have facilitated the early adoption ofmany novel theranostic pairs. A notable example of this was the recent publication of the first-inhuman single photon emission computed tomography /computed tomography of terbium-prostate-specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer by the King Hussein Cancer Center team.10,11 In many developing countries, NM specialists are often perceived by other specialties as diagnostic physicians. This perception remains prominent in regions where the i

{"title":"Theranostics in Developing Countries: Addressing Challenges and Potentials from Training to Practice.","authors":"Akram Al-Ibraheem","doi":"10.1055/s-0043-1774733","DOIUrl":"https://doi.org/10.1055/s-0043-1774733","url":null,"abstract":"In recent times, nuclear medicine (NM) has witnessed noteworthy expansion, presenting several technologies and procedures that aid in the identification and management of various illnesses and disorders. The current era of globalization has posed difficulties for health care systems in managing the escalating incidence of noncommunicable diseases (NCDs) in developing countries.1 The use of radionuclide pairs for both diagnosis and treatment, known as theranostics, has become increasingly popular in developing countries.2 This is due to the availability of more resources, expertise, and personnel. Although the idea of combining therapyand diagnosis has been studied and utilized formany years, recent advancements in cancer genomics and hallmarks have led to significant progress in the field of theranostics over the past two decades. Nowadays, NM theranostics are improving the prognosis of cancer patients through the use of lutetium-based radionuclide therapies, whichhavebeenvalidated in phase III clinical trialswith high confidence.3,4 To date, many Southeast Asian, Middle Eastern, and Latin American countries have continuously offered advanced NM services.5–7 Some of these countries serve as exemplary models in the developing world, as they leverage their limited resources to generate numerous radionuclides, conduct practical research projects, and significantly contribute to the progress of theranostics. Additionally, they have augmented the size of their NM workforce by offering specialized NM training programs as well as fellowship programs. Although theranostics has made substantial strides and improvements, a discernible discrepancy persists among developing countries. This disparity is particularly noticeable in theMiddle East, where numerous countries are embroiled inwars and conflicts.8 These developing countries are currently encountering difficulties keeping up with the latest advancements in theranostics. Presently, there are over 2,000 NM centers in the region.9 Several countries in the region have made investments in establishing production facilities. This investment has contributed to a noticeable increase in the local supply of essential radiopharmaceuticals. It is noteworthy that several centers of excellence in NM are currently involved in providing early experience with innovative theranostic agents, despite several limitations. This has been made possible due to flexible national and institutional regulations that have facilitated the early adoption ofmany novel theranostic pairs. A notable example of this was the recent publication of the first-inhuman single photon emission computed tomography /computed tomography of terbium-prostate-specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer by the King Hussein Cancer Center team.10,11 In many developing countries, NM specialists are often perceived by other specialties as diagnostic physicians. This perception remains prominent in regions where the i","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"22 3","pages":"171-173"},"PeriodicalIF":0.6,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49682940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

3D-OSEM versus FORE + OSEM: Optimal Reconstruction Algorithm for FDG PET with a Short Acquisition Time. 3D-OSEM与FORE + OSEM：短采集时间FDG PET的最佳重建算法。

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-09-13 eCollection Date: 2023-09-01 DOI: 10.1055/s-0043-1774418

Keisuke Tsuda, Takayuki Suzuki, Kazuhito Toya, Eisuke Sato, Hirofumi Fujii

Objective In this study, we investigated the optimal reconstruction algorithm in fluorodeoxyglucose (FDG) positron emission tomography (PET) with a short acquisition time. Materials and Methods In the phantom study, six spheres filled with FDG solution (sphere size: 6.23-37 mm; radioactivity ratio of spheres to background = 8:1) and placed in a National Electrical Manufacturers Association phantom were evaluated. Image acquisition time was 15 to 180 seconds, and the obtained image data were reconstructed using each of the Fourier rebinning (FORE) + ordered subsets expectation-maximization (OSEM) and 3D-OSEM algorithms. In the clinical study, mid-abdominal images of 19 patients were evaluated using regions of interest placed on areas of low, intermediate, and high radioactivity. All obtained images were investigated visually, and quantitatively using maximum standardized uptake value (SUV) and coefficient of variation (CV). Results In the phantom study, FORE + OSEM images with a short acquisition time had large CVs (poor image quality) but comparatively constant maximum SUVs. 3D-OSEM images showed comparatively constant CVs (good image quality) but significantly low maximum SUVs. The results of visual evaluation were well correlated with those of quantitative evaluation. Small spheres were obscured on 3D-OSEM images with short acquisition time, but image quality was not greatly deteriorated. The clinical and phantom studies yielded similar results. Conclusion FDG PET images with a short acquisition time reconstructed by FORE + OSEM showed poorer image quality than by 3D-OSEM. However, images obtained with a short acquisition time and reconstructed with FORE + OSEM showed clearer FDG uptake and more useful than 3D-OSEM in the light of the detection of lesions.

客观的在本研究中，我们研究了短采集时间的氟脱氧葡萄糖（FDG）正电子发射断层扫描（PET）的最佳重建算法。材料和方法在体模研究中，用FDG溶液填充六个球体（球体尺寸：6.23-37 mm；球体与背景的放射性比 = 8:1）并放置在美国国家电气制造商协会体模中。图像采集时间为15至180 秒，并且使用每个傅立叶重构（FORE）来重构所获得的图像数据 + 有序子集期望最大化（OSEM）和3D-OSEM算法。在临床研究中，使用位于低、中、高放射性区域的感兴趣区域对19名患者的腹部图像进行了评估。使用最大标准化摄取值（SUV）和变异系数（CV）对所有获得的图像进行视觉和定量研究。后果在体模研究中，FORE + 采集时间短的OSEM图像具有大的CV（图像质量差），但相对恒定的最大SUV。3D-OSEM图像显示了相对恒定的CV（良好的图像质量），但最大SUV明显较低。视觉评价的结果与定量评价的结果有很好的相关性。在3D-OSEM图像上，小球体在较短的采集时间内被遮挡，但图像质量没有显著恶化。临床和体模研究得出了类似的结果。结论 FORE重建采集时间短的FDG PET图像 + OSEM显示出比3D-OSEM更差的图像质量。然而，用短采集时间获得并用FORE重建的图像 + OSEM显示出比3D-OSEM更清晰的FDG摄取，并且在检测病变方面更有用。

{"title":"3D-OSEM versus FORE + OSEM: Optimal Reconstruction Algorithm for FDG PET with a Short Acquisition Time.","authors":"Keisuke Tsuda, Takayuki Suzuki, Kazuhito Toya, Eisuke Sato, Hirofumi Fujii","doi":"10.1055/s-0043-1774418","DOIUrl":"https://doi.org/10.1055/s-0043-1774418","url":null,"abstract":"Objective In this study, we investigated the optimal reconstruction algorithm in fluorodeoxyglucose (FDG) positron emission tomography (PET) with a short acquisition time. Materials and Methods In the phantom study, six spheres filled with FDG solution (sphere size: 6.23-37 mm; radioactivity ratio of spheres to background = 8:1) and placed in a National Electrical Manufacturers Association phantom were evaluated. Image acquisition time was 15 to 180 seconds, and the obtained image data were reconstructed using each of the Fourier rebinning (FORE) + ordered subsets expectation-maximization (OSEM) and 3D-OSEM algorithms. In the clinical study, mid-abdominal images of 19 patients were evaluated using regions of interest placed on areas of low, intermediate, and high radioactivity. All obtained images were investigated visually, and quantitatively using maximum standardized uptake value (SUV) and coefficient of variation (CV). Results In the phantom study, FORE + OSEM images with a short acquisition time had large CVs (poor image quality) but comparatively constant maximum SUVs. 3D-OSEM images showed comparatively constant CVs (good image quality) but significantly low maximum SUVs. The results of visual evaluation were well correlated with those of quantitative evaluation. Small spheres were obscured on 3D-OSEM images with short acquisition time, but image quality was not greatly deteriorated. The clinical and phantom studies yielded similar results. Conclusion FDG PET images with a short acquisition time reconstructed by FORE + OSEM showed poorer image quality than by 3D-OSEM. However, images obtained with a short acquisition time and reconstructed with FORE + OSEM showed clearer FDG uptake and more useful than 3D-OSEM in the light of the detection of lesions.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"22 3","pages":"234-243"},"PeriodicalIF":0.6,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49682934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Prognostic Value of Sequential ¹⁸ F-FDG PET/CT Metabolic Parameters in Outcomes of Upper-Third Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Chemoradiotherapy. 序列18F-FDG PET/CT代谢参数对接受明确放化疗的上三分之一食管鳞状细胞癌患者预后的价值。

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-09-13 eCollection Date: 2023-09-01 DOI: 10.1055/s-0043-1774417

Le Ngoc Ha, Nguyen Dinh Chau, Bui Quang Bieu, Mai Hong Son

Objective The aim of this study is to determine prognostic values of sequential ¹⁸ F-FDG PET/CT metabolic parameters in locally advanced esophageal squamous cell carcinoma (ESCC) patients treated with definitive chemoradiotherapy. Materials and Methods Forty locally advanced ESCC patients treated with definitive chemoradiotherapy (dCRT) who received pre-treatment ¹⁸ F-FDG PET/CT (PET1) and 3-months post-treatment ¹⁸ F-FDG PET/CT (PET2) were enrolled in the prospective study. ¹⁸ F-FDG PET parameters of the primary tumor including maximum and mean standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were calculated on PET delineated primary tumor. Using Kaplan-Meier curves to estimated overall survival (OS), progression-free survival (PFS), and local-regional control (LRC). Cox regression analysis was performed to find significant prognostic factors for survival. Results With a median follow-up of 13.5 months, the 4-year OS, PFS, and LRC rates were 67.3%, 52.6%, and 53.4% respectively. Patients with MTV 2 > 5.7 had lower OS, PFS, and LRC rates than the lower MTV 2 group (p < 0.05). Univariate Cox regression analysis showed that MTV2 was a significant prognostic factor for OS, PFS, and LRC (p < 0.05). Conclusion MTV parameter of sequential ¹⁸ F-FDG PET/CT could be used as a prognostic factor for OS, PFS, and LRC in locally advanced ESCC patients treated with dCRT.

客观的本研究的目的是确定连续18F-FDG PET/CT代谢参数对接受明确放化疗的局部晚期食管鳞状细胞癌（ESCC）患者的预后价值。材料和方法 40名接受明确放化疗（dCRT）治疗的局部晚期ESCC患者在治疗前接受了18F-FDG PET/CT（PET1）治疗，在治疗后3个月接受了18F-FDG PET/COT（PET2）治疗。在PET描绘的原发肿瘤上计算原发肿瘤的18个F-FDG PET参数，包括最大和平均标准化摄取值（SUVmax、SUVmean）、代谢肿瘤体积（MTV）和总损伤糖酵解（TLG）。使用Kaplan-Meier曲线来估计总生存期（OS）、无进展生存期（PFS）和局部区域对照（LRC）。进行了Cox回归分析，以寻找重要的生存预后因素。后果中位随访13.5个月，4年OS、PFS和LRC的发生率分别为67.3%、52.6%和53.4%。MTV2＞5.7的患者OS、PFS和LRC发生率低于MTV2组（p＜0.05）。单变量Cox回归分析表明，MTV2是OS、PFS、LRC的重要预后因素（p＜0.01）连续18F-FDG PET/CT的MTV参数可作为接受dCRT治疗的局部晚期ESCC患者OS、PFS和LRC的预后因素。

{"title":"The Prognostic Value of Sequential 18 F-FDG PET/CT Metabolic Parameters in Outcomes of Upper-Third Esophageal Squamous Cell Carcinoma Patients Treated with Definitive Chemoradiotherapy.","authors":"Le Ngoc Ha, Nguyen Dinh Chau, Bui Quang Bieu, Mai Hong Son","doi":"10.1055/s-0043-1774417","DOIUrl":"https://doi.org/10.1055/s-0043-1774417","url":null,"abstract":"Objective The aim of this study is to determine prognostic values of sequential 18 F-FDG PET/CT metabolic parameters in locally advanced esophageal squamous cell carcinoma (ESCC) patients treated with definitive chemoradiotherapy. Materials and Methods Forty locally advanced ESCC patients treated with definitive chemoradiotherapy (dCRT) who received pre-treatment 18 F-FDG PET/CT (PET1) and 3-months post-treatment 18 F-FDG PET/CT (PET2) were enrolled in the prospective study. 18 F-FDG PET parameters of the primary tumor including maximum and mean standardized uptake values (SUVmax, SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were calculated on PET delineated primary tumor. Using Kaplan-Meier curves to estimated overall survival (OS), progression-free survival (PFS), and local-regional control (LRC). Cox regression analysis was performed to find significant prognostic factors for survival. Results With a median follow-up of 13.5 months, the 4-year OS, PFS, and LRC rates were 67.3%, 52.6%, and 53.4% respectively. Patients with MTV 2 > 5.7 had lower OS, PFS, and LRC rates than the lower MTV 2 group (p < 0.05). Univariate Cox regression analysis showed that MTV2 was a significant prognostic factor for OS, PFS, and LRC (p < 0.05). Conclusion MTV parameter of sequential 18 F-FDG PET/CT could be used as a prognostic factor for OS, PFS, and LRC in locally advanced ESCC patients treated with dCRT.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"22 3","pages":"226-233"},"PeriodicalIF":0.6,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49682939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Establishing a Cutoff Serum Thyroglobulin Value for the Diagnosis and Management of Well-Differentiated Thyroid Cancer. 血清甲状腺球蛋白对癌症分化良好的诊断和治疗价值的建立

IF 0.6 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

World Journal of Nuclear Medicine

Pub Date : 2023-09-06 eCollection Date: 2023-09-01 DOI: 10.1055/s-0043-1771286

Jiwan Paudel

Objective The aim of this study was to define a cutoff serum thyroglobulin (Tg) level associated with either residual or metastasis that may help decide postoperative radioactive iodine (RAI) scan and treatment in differentiated thyroid cancer (DTC) patients residing in low-income countries like Nepal. Methods We prospectively studied a total of 81 patients (female-to-male ratio of 3.0:1; mean age: 37.3 ± 14.0 years, within age range of 14-88 years) who underwent total thyroidectomy with/without neck dissection and were referred for RAI whole-body scan (WBS) ± RAI ablation or adjuvant treatment in the department of Nuclear Medicine, Chitwan Medical College. We calculated the cutoff value of Tg using receiver operating characteristic (ROC) curve analysis. Results Forty-six of 81 patients (56.7%) had remnants in the thyroid bed, 26/81 (32.1%) had regional lymph node metastasis, 9/81 (11.1%) had distant lymph node metastasis, 3/81 (3.7%) had lung metastases, and only 1/81 (1.2%) had bone metastases. RAI WBS was positive in 61/81 (75.3%) patients and negative in 20/81 (24.7%) patients. Seventeen of 81 (20.9%) patients had negative RAI scans with low serum Tg levels; only 3/81 (3.7%) patients had Tg elevated negative RAI scan (TENIS). Although scan was positive in 61/81 (75.3%) patients, 64/81 (79.0%) patients received treatment with RAI, of which 3/81 (3.7%) patients were TENIS patients. There was a significant difference in serum Tg levels between patients who received or did not receive RAI ablation or treatment ( p < 0.05). On ROC curve analysis, the cutoff value of Tg levels between patients who received and did not receive treatment was 2.9 ng/mL (sensitivity: 85.9%; specificity: 94.1%; positive predictive value [PPV], 98.2%; negative predictive value [NPV]: 64.0%; AUC: 0.938). Conclusion We identified a cutoff value of 2.9 ng/mL between patients who required or did not require treatment with high sensitivity, specificity, and PPVs.

摘要目的本研究的目的是确定与残留或转移相关的血清甲状腺球蛋白(Tg)水平，这可能有助于决定生活在尼泊尔等低收入国家的分化型甲状腺癌(DTC)患者术后放射性碘(RAI)扫描和治疗。方法前瞻性研究81例患者(男女比例为3.0:1;平均年龄:37.3±14.0岁，年龄范围14-88岁)，行甲状腺全切除术伴/不伴颈部清扫，转介于Chitwan医学院核医学院行RAI全身扫描(WBS)±RAI消融或辅助治疗。我们使用受试者工作特征(ROC)曲线分析计算Tg的截止值。结果81例患者中有46例(56.7%)甲状腺床残留，26/81例(32.1%)有局部淋巴结转移，9/81例(11.1%)有远处淋巴结转移，3/81例(3.7%)有肺转移，1/81例(1.2%)有骨转移。61/81(75.3%)患者的RAI WBS呈阳性，20/81(24.7%)患者呈阴性。81例患者中17例(20.9%)RAI扫描阴性，血清Tg水平低;仅3/81(3.7%)患者出现Tg升高(TENIS)。61/81(75.3%)患者扫描呈阳性，64/81(79.0%)患者接受RAI治疗，其中3/81(3.7%)患者为TENIS患者。接受或未接受RAI消融或治疗的患者血清Tg水平差异有统计学意义(p < 0.05)。ROC曲线分析显示，接受和未接受治疗的患者Tg水平的临界值为2.9 ng/mL(敏感性:85.9%;特异性:94.1%;阳性预测值[PPV]为98.2%;阴性预测值[NPV]: 64.0%;AUC: 0.938)。结论:我们确定了需要或不需要高敏感性、特异性和ppv治疗的患者之间的临界值为2.9 ng/mL。

{"title":"Establishing a Cutoff Serum Thyroglobulin Value for the Diagnosis and Management of Well-Differentiated Thyroid Cancer.","authors":"Jiwan Paudel","doi":"10.1055/s-0043-1771286","DOIUrl":"10.1055/s-0043-1771286","url":null,"abstract":"Objective The aim of this study was to define a cutoff serum thyroglobulin (Tg) level associated with either residual or metastasis that may help decide postoperative radioactive iodine (RAI) scan and treatment in differentiated thyroid cancer (DTC) patients residing in low-income countries like Nepal. Methods We prospectively studied a total of 81 patients (female-to-male ratio of 3.0:1; mean age: 37.3 ± 14.0 years, within age range of 14-88 years) who underwent total thyroidectomy with/without neck dissection and were referred for RAI whole-body scan (WBS) ± RAI ablation or adjuvant treatment in the department of Nuclear Medicine, Chitwan Medical College. We calculated the cutoff value of Tg using receiver operating characteristic (ROC) curve analysis. Results Forty-six of 81 patients (56.7%) had remnants in the thyroid bed, 26/81 (32.1%) had regional lymph node metastasis, 9/81 (11.1%) had distant lymph node metastasis, 3/81 (3.7%) had lung metastases, and only 1/81 (1.2%) had bone metastases. RAI WBS was positive in 61/81 (75.3%) patients and negative in 20/81 (24.7%) patients. Seventeen of 81 (20.9%) patients had negative RAI scans with low serum Tg levels; only 3/81 (3.7%) patients had Tg elevated negative RAI scan (TENIS). Although scan was positive in 61/81 (75.3%) patients, 64/81 (79.0%) patients received treatment with RAI, of which 3/81 (3.7%) patients were TENIS patients. There was a significant difference in serum Tg levels between patients who received or did not receive RAI ablation or treatment ( p < 0.05). On ROC curve analysis, the cutoff value of Tg levels between patients who received and did not receive treatment was 2.9 ng/mL (sensitivity: 85.9%; specificity: 94.1%; positive predictive value [PPV], 98.2%; negative predictive value [NPV]: 64.0%; AUC: 0.938). Conclusion We identified a cutoff value of 2.9 ng/mL between patients who required or did not require treatment with high sensitivity, specificity, and PPVs.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"22 1","pages":"208-216"},"PeriodicalIF":0.6,"publicationDate":"2023-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48001005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiation Safety and External Radiation Exposure Rate of Patients Receiving I-131 Therapy for Hyperthyroidism and Remnant Ablation as Outpatient: An Institutional Experience 门诊接受I-131甲状腺功能亢进和残余消融治疗的患者的辐射安全性和外照射暴露率：一项机构经验

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-09-06 DOI: 10.1055/s-0043-1771285

Nisha Bhatia, Vandana K. Dhingra, Pulkit Mittal, Sunil Saini

Abstract Objective Our objective was to study the radiation exposure rate as function of time in the administration of radioiodine iodine-131 (I-131) for the treatment of thyrotoxicosis or Graves' disease and remnant ablation on an outpatient basis at the Department of Nuclear Medicine, and also, to study the impact of revised discharge criteria for radioiodine therapy enforced by the Atomic Energy Regulatory Board (AERB) of India. Materials and Methods This study included patients who underwent low-dose radioiodine therapy using I-131. Patients were classified into two different groups, that is, group A and group B. Group A included patients receiving low dose I-131 for the treatment of thyrotoxicosis, whereas group B included patients receiving I-131 therapy for the ablation of residual thyroid tissue after total thyroidectomy. The radiation exposure rate was measured using a radiation detector in milli roentgen per hour (mR/h) at 5 cm distance of stomach and neck levels and with the patient standing at the distance of 1 m after oral administration of I-131 at 0, 1, and 2 hours. Results A total of 134 (17 males and 117 females) patients were included in the study. Group A comprised 102 (14 male and 88 females) patients and group B of 32 (3 males and 29 females) patients. At the neck level, the average exposure rate in group A versus group B after 0, 1, and 2 hours was observed to be 6.9 versus 22.27 mR/h, 33.67 versus 43.39 mR/h, and 41.75 versus 48.90 mR/h, respectively. At the stomach level, the exposure rate was 23.65 versus 71.32 mR/h, 13.27 versus 48.45 mR/h, and 9.91 versus 39.43 mR/h after 0, 1, and 2 hours, respectively. At a distance of 1 m, the exposure rate was 1.31 versus 2.99 mR/h, 1.05 versus 2.58 mR/h, and 0.92 versus 2.21 mR/h, respectively. Conclusion Exposure rate measured for patients treated with up to 1,110 MBq (30 mCi) of I-131 was under permissible limits as per revised discharged limits, that is, 50 µSv/h (5 mR/h) prescribed by AERB, India. The patients undergoing radioiodine therapy I-131 (up to 1,110 MBq/30 mCi) can be discharged safely 2 hours postadministration following good work practice along with providing proper radiation safety instructions to patients.

抽象目标我们的目的是研究放射性碘-131（I-131）在核医学部门诊治疗甲状腺毒症或Graves病和残余消融时的辐射暴露率随时间的变化，研究印度原子能管理委员会（AERB）执行的放射性碘治疗的修订排放标准的影响。材料和方法本研究包括使用I-131进行低剂量放射性碘治疗的患者。患者分为两组，即A组和B组。A组包括接受低剂量I-131治疗甲状腺毒症的患者，而B组包括接受I-131治疗的患者，用于甲状腺全切除术后残留甲状腺组织的消融。使用辐射探测器在5 胃和颈部水平的cm距离，并且在0、1和2口服I-131后患者站在1m的距离处小时。后果共有134名患者（17名男性和117名女性）被纳入研究。A组包括102名患者（14名男性和88名女性），B组包括32名患者（3名男性和29名女性）。在颈部水平，0、1和2后，A组与B组的平均暴露率小时分别为6.9对22.27 mR/h、33.67对43.39 mR/h和41.75对48.90 mR/h。在胃水平，0、1和2后，暴露率分别为23.65和71.32 mR/h、13.27和48.45 mR/h以及9.91和39.43 mR/h 小时。在1m的距离处，暴露率分别为1.31对2.99mR/h、1.05对2.58mR/h和0.92对2.21mR/h。结论根据修订后的出院限值，即印度AERB规定的50µSv/h（5 mR/h），接受高达1110 MBq（30 mCi）I-131治疗的患者的暴露率低于允许限值。接受放射性碘治疗的患者I-131（最高1110 MBq/30 mCi）可以安全出院2 遵循良好的工作实践，并向患者提供适当的辐射安全指导。

{"title":"Radiation Safety and External Radiation Exposure Rate of Patients Receiving I-131 Therapy for Hyperthyroidism and Remnant Ablation as Outpatient: An Institutional Experience","authors":"Nisha Bhatia, Vandana K. Dhingra, Pulkit Mittal, Sunil Saini","doi":"10.1055/s-0043-1771285","DOIUrl":"https://doi.org/10.1055/s-0043-1771285","url":null,"abstract":"Abstract Objective Our objective was to study the radiation exposure rate as function of time in the administration of radioiodine iodine-131 (I-131) for the treatment of thyrotoxicosis or Graves' disease and remnant ablation on an outpatient basis at the Department of Nuclear Medicine, and also, to study the impact of revised discharge criteria for radioiodine therapy enforced by the Atomic Energy Regulatory Board (AERB) of India. Materials and Methods This study included patients who underwent low-dose radioiodine therapy using I-131. Patients were classified into two different groups, that is, group A and group B. Group A included patients receiving low dose I-131 for the treatment of thyrotoxicosis, whereas group B included patients receiving I-131 therapy for the ablation of residual thyroid tissue after total thyroidectomy. The radiation exposure rate was measured using a radiation detector in milli roentgen per hour (mR/h) at 5 cm distance of stomach and neck levels and with the patient standing at the distance of 1 m after oral administration of I-131 at 0, 1, and 2 hours. Results A total of 134 (17 males and 117 females) patients were included in the study. Group A comprised 102 (14 male and 88 females) patients and group B of 32 (3 males and 29 females) patients. At the neck level, the average exposure rate in group A versus group B after 0, 1, and 2 hours was observed to be 6.9 versus 22.27 mR/h, 33.67 versus 43.39 mR/h, and 41.75 versus 48.90 mR/h, respectively. At the stomach level, the exposure rate was 23.65 versus 71.32 mR/h, 13.27 versus 48.45 mR/h, and 9.91 versus 39.43 mR/h after 0, 1, and 2 hours, respectively. At a distance of 1 m, the exposure rate was 1.31 versus 2.99 mR/h, 1.05 versus 2.58 mR/h, and 0.92 versus 2.21 mR/h, respectively. Conclusion Exposure rate measured for patients treated with up to 1,110 MBq (30 mCi) of I-131 was under permissible limits as per revised discharged limits, that is, 50 µSv/h (5 mR/h) prescribed by AERB, India. The patients undergoing radioiodine therapy I-131 (up to 1,110 MBq/30 mCi) can be discharged safely 2 hours postadministration following good work practice along with providing proper radiation safety instructions to patients.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2023-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47601736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adverse Allergic Reaction to Intrathecally Administered Technetium-99m Diethylenetriamine Pentaacetate: A Case Report 鞘内注射锝-99m五乙酸二乙三胺的不良过敏反应1例

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-09-06 DOI: 10.1055/s-0043-1771281

Ahalya Nair, Guneshwaran Poolpandian, Kabilash Dhayalan, Jayaram Saibaba

Abstract Intrathecal administration of radiopharmaceuticals is an infrequently performed procedure in most nuclear medicine facilities. It is possible that adverse allergic reactions following the intrathecal administration of radiopharmaceuticals often go unreported. Here we present a case of spontaneous cerebrospinal fluid rhinorrhea with recurrent bacterial meningitis, who underwent radionuclide cisternography for localization of the site of leak and developed an adverse allergic reaction following the intrathecal administration of technetium-99m diethylenetriamine pentaacetate that resolved with appropriate treatment. Imaging, however, could be carried out to our satisfaction and the allergic reaction did not interfere with, or result in discontinuation of the scan procedure.

摘要在大多数核医学设施中，鞘内给药是一种罕见的操作。这是可能的，在鞘内给予放射性药物的不良过敏反应往往没有报道。在此，我们报告一例自发性脑脊液鼻漏伴复发性细菌性脑膜炎的病例，患者接受了放射性核素池造影以定位泄漏部位，并在鞘内给予锝-99m二乙烯三胺五乙酸酯后发生了不良过敏反应，经适当治疗后消退。然而，成像可以进行到我们满意，过敏反应没有干扰，或导致停止扫描程序。

引用次数: 0

Role of 18 F-FDG PET-CT in Urethral Malignant Melanoma and Analysis of the UK Guidelines on Ano-uro-genital Melanomas 18f - fdg PET-CT在尿道恶性黑色素瘤中的作用及对英国泌尿生殖器黑色素瘤指南的分析

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-09-06 DOI: 10.1055/s-0043-1771280

Abhishek Mahato, Anurag Jain, M.G. Manoj, Richa Joshi

Abstract Urethral melanomas are a rare subtype of noncutaneous melanomas. The disease has a tendency to have skip lesions and early metastases as compared with cutaneous melanomas. The role of fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography computed tomography (PET-CT) is well established in cases of cutaneous melanomas and is recommended by the National Comprehensive Cancer Network (NCCN) for stage IIB to IV cancer. There are no established guidelines on the management of noncutaneous melanomas; however, a recently published United Kingdom national guideline aims to streamline the management of ano-uro-genital melanomas. The guideline describes a very limited role in the use of 18 F-FDG PET-CT in this case scenario. The tendency to skip lesions, early metastases, involvement of brain parenchyma, and finally the usage of anti-PD-1 medications are key areas where 18 F-FDG PET-CT has shown superiority over CT scan. With this case report, we aim to highlight the strength of 18 F-FDG PET-CT in the management of urethral melanomas, which can be extrapolated to other ano-uro-genital melanomas.

摘要尿道黑色素瘤是一种罕见的非皮肤黑色素瘤亚型。与皮肤黑色素瘤相比，该病有跳跃性病变和早期转移的趋势。氟-18氟脱氧葡萄糖（18F-FDG）正电子发射断层扫描计算机断层扫描（PET-CT）在皮肤黑色素瘤病例中的作用已得到充分证实，并被国家综合癌症网络（NCCN）推荐用于癌症IIB至IV期。目前还没有关于非皮肤黑色素瘤管理的既定指南；然而，英国最近发布的一项国家指南旨在简化肛门生殖器黑色素瘤的管理。该指南描述了在这种情况下使用18F-FDG PET-CT的作用非常有限。跳过病变的趋势、早期转移、脑实质受累，以及最终使用抗PD-1药物，是18F-FDG PET-CT显示出优于CT扫描的关键领域。在本病例报告中，我们旨在强调18F-FDG PET-CT在治疗尿道黑色素瘤方面的优势，这可以推广到其他非尿道生殖器黑色素瘤。

{"title":"Role of 18 F-FDG PET-CT in Urethral Malignant Melanoma and Analysis of the UK Guidelines on Ano-uro-genital Melanomas","authors":"Abhishek Mahato, Anurag Jain, M.G. Manoj, Richa Joshi","doi":"10.1055/s-0043-1771280","DOIUrl":"https://doi.org/10.1055/s-0043-1771280","url":null,"abstract":"Abstract Urethral melanomas are a rare subtype of noncutaneous melanomas. The disease has a tendency to have skip lesions and early metastases as compared with cutaneous melanomas. The role of fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography computed tomography (PET-CT) is well established in cases of cutaneous melanomas and is recommended by the National Comprehensive Cancer Network (NCCN) for stage IIB to IV cancer. There are no established guidelines on the management of noncutaneous melanomas; however, a recently published United Kingdom national guideline aims to streamline the management of ano-uro-genital melanomas. The guideline describes a very limited role in the use of 18 F-FDG PET-CT in this case scenario. The tendency to skip lesions, early metastases, involvement of brain parenchyma, and finally the usage of anti-PD-1 medications are key areas where 18 F-FDG PET-CT has shown superiority over CT scan. With this case report, we aim to highlight the strength of 18 F-FDG PET-CT in the management of urethral melanomas, which can be extrapolated to other ano-uro-genital melanomas.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":"352 ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2023-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41272306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimization of the Acquisition Time and Injected Dose of 18 F-Fluorodeoxyglucose Based on Patient Specifications for High-Sensitive Positron Emission Tomography/Computed Tomography Scanner 基于高灵敏度正电子发射断层扫描/计算机断层扫描患者规范的18F-氟脱氧葡萄糖采集时间和注射剂量的优化

IF 0.6

World Journal of Nuclear Medicine

Pub Date : 2023-09-06 DOI: 10.1055/s-0043-1771284

M. Al-Fatlawi, Farideh Pak, Saeed Farzanefar, Yalda Salehi, Abbas Monsef, P. Sheikhzadeh

Abstract: Background This study was aimed to optimize the fluorodeoxyglucose (FDG)-administered dose and scan time based on patient specifications using a highly sensitive five-ring bismuth germanium oxide (BGO)-based positron emission tomography/computed tomography (PET/CT) scanner (Discovery IQ). Methods We retrospectively analyzed 101 whole-body 18 F-FDG PET/CT images. Patient data were reconstructed using ordered subset expectation maximization with resolution recovery algorithms (OSEM + SharpIR). Signal-to-noise ratio (SNR) was calculated for each patient, standardized to SNR norm , and plotted against three body index parameters (weight, body mass index, and lean body mass). Two professional physicians blindly examined image quality at different patient time per bed positions to determine the minimum acceptable quality. To select images of acceptable quality, the noise index parameter was also measured. A new dose-time product (DTP) was established for each patient, and a predicted injected dose was assumed. Results We found an almost linear association between patient weight and normalized SNR, and patient weight had the highest R 2 in the fitting. The redesigned DTP can reduce results by approximately 74 and 38% compared with ordinary DTP for 80- and 160-s scan durations. The new dose regimen formula was found to be DTP = c/t × m 1.24 , where m is the patient weight, t is the scan time per bed position, and c is 1.8 and 4.3 for acceptable and higher confidence states, respectively, in Discovery IQ PET/CT. Conclusion Patient weight is the best clinical parameter for the implementation of 18 F-FDG PET/CT image quality assessment. A new dose-time regimen based on body weight was proposed for use in highly sensitive five-ring BGO PET-CT scanners to significantly reduce the injection dose and scan times while maintaining sufficient image quality for diagnosis.

摘要：背景本研究旨在使用基于高灵敏度五环氧化铋锗（BGO）的正电子发射断层扫描/计算机断层扫描（PET/CT）扫描仪（Discovery IQ），根据患者规格优化氟脱氧葡萄糖（FDG）的给药剂量和扫描时间。方法我们回顾性分析了101例全身18F-FDG PET/CT图像。使用有序子集期望最大化和分辨率恢复算法（OSEM+SharpIR）重建患者数据。计算每个患者的信噪比（SNR），标准化为SNR标准，并根据三个身体指数参数（体重、体重指数和瘦体重）绘制。两位专业医生盲目地检查了每个床位不同患者时间的图像质量，以确定可接受的最低质量。为了选择质量可接受的图像，还测量了噪声指数参数。为每位患者建立新的剂量-时间乘积（DTP），并假设预测的注射剂量。后果我们发现患者体重和归一化SNR之间几乎呈线性关系，并且患者体重在拟合中具有最高的R2。与普通DTP相比，在80秒和160秒的扫描持续时间内，重新设计的DTP可以将结果减少约74%和38%。新的给药方案是DTP = c/t × m 1.24，其中m是患者体重，t是每个床位的扫描时间，对于Discovery IQ PET/CT中的可接受和较高置信度状态，c分别为1.8和4.3。结论患者体重是实施18F-FDG PET/CT图像质量评估的最佳临床参数。提出了一种基于体重的新剂量-时间方案，用于高灵敏度的五环BGO PET-CT扫描仪，以显著减少注射剂量和扫描时间，同时保持足够的诊断图像质量。

{"title":"Optimization of the Acquisition Time and Injected Dose of 18 F-Fluorodeoxyglucose Based on Patient Specifications for High-Sensitive Positron Emission Tomography/Computed Tomography Scanner","authors":"M. Al-Fatlawi, Farideh Pak, Saeed Farzanefar, Yalda Salehi, Abbas Monsef, P. Sheikhzadeh","doi":"10.1055/s-0043-1771284","DOIUrl":"https://doi.org/10.1055/s-0043-1771284","url":null,"abstract":"Abstract: Background This study was aimed to optimize the fluorodeoxyglucose (FDG)-administered dose and scan time based on patient specifications using a highly sensitive five-ring bismuth germanium oxide (BGO)-based positron emission tomography/computed tomography (PET/CT) scanner (Discovery IQ). Methods We retrospectively analyzed 101 whole-body 18 F-FDG PET/CT images. Patient data were reconstructed using ordered subset expectation maximization with resolution recovery algorithms (OSEM + SharpIR). Signal-to-noise ratio (SNR) was calculated for each patient, standardized to SNR norm , and plotted against three body index parameters (weight, body mass index, and lean body mass). Two professional physicians blindly examined image quality at different patient time per bed positions to determine the minimum acceptable quality. To select images of acceptable quality, the noise index parameter was also measured. A new dose-time product (DTP) was established for each patient, and a predicted injected dose was assumed. Results We found an almost linear association between patient weight and normalized SNR, and patient weight had the highest R 2 in the fitting. The redesigned DTP can reduce results by approximately 74 and 38% compared with ordinary DTP for 80- and 160-s scan durations. The new dose regimen formula was found to be DTP = c/t × m 1.24 , where m is the patient weight, t is the scan time per bed position, and c is 1.8 and 4.3 for acceptable and higher confidence states, respectively, in Discovery IQ PET/CT. Conclusion Patient weight is the best clinical parameter for the implementation of 18 F-FDG PET/CT image quality assessment. A new dose-time regimen based on body weight was proposed for use in highly sensitive five-ring BGO PET-CT scanners to significantly reduce the injection dose and scan times while maintaining sufficient image quality for diagnosis.","PeriodicalId":23742,"journal":{"name":"World Journal of Nuclear Medicine","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2023-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47130800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0